## ilaria Bacigalupo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4430329/publications.pdf

Version: 2024-02-01

430442 395343 1,090 34 18 33 citations g-index h-index papers 35 35 35 1641 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A nationwide survey of Italian Centers for Cognitive Disorders and Dementia on the provision of care for international migrants. European Journal of Neurology, 2022, 29, 1892-1902.	1.7	5
2	Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. GeroScience, 2021, 43, 1039-1051.	2.1	25
3	The Italian national survey on Coronavirus disease 2019 epidemic spread in nursing homes. International Journal of Geriatric Psychiatry, 2021, 36, 873-882.	1.3	21
4	Anticancer drugs repurposed for Alzheimer's disease: a systematic review. Alzheimer's Research and Therapy, 2021, 13, 96.	3.0	11
5	Decreasing trend in the incidence and prevalence of dementia: a systematic review. Minerva Medica, 2021, 112, 430-440.	0.3	4
6	Supporting and Protecting People with Dementia in the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2021, 83, 43-49.	1.2	2
7	A National Survey of Centers for Cognitive Disorders and Dementias in Italy. Journal of Alzheimer's Disease, 2021, 83, 1849-1857.	1.2	11
8	Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 584.	0.7	3
9	A systematic review on the epidemiology of normal pressure hydrocephalus. Acta Neurologica Scandinavica, 2020, 141, 101-114.	1.0	22
10	Integrated care pathways on dementia in Italy: a survey testing the compliance with a national guidance. Neurological Sciences, 2020, 41, 917-924.	0.9	4
11	Mild Cognitive Impairment in the Migrant Population Living in Europe: An Epidemiological Estimation of the Phenomenon. Journal of Alzheimer's Disease, 2020, 73, 715-721.	1.2	6
12	Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 68.	1.1	9
13	Age and sex prevalence estimate of Joubert syndrome in Italy. Neurology, 2020, 94, e797-e801.	1.5	26
14	Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF. Frontiers in Aging Neuroscience, 2019, 11, 282.	1.7	8
15	MicroRNAs and mild cognitive impairment: A systematic review. Ageing Research Reviews, 2019, 50, 131-141.	<b>5.</b> 0	34
16	An Estimate of Attributable Cases of Alzheimer Disease and Vascular Dementia due to Modifiable Risk Factors: The Impact of Primary Prevention in Europe and in Italy. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 60-71.	0.6	38
17	A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe: Estimates from the Highest-Quality Studies Adopting the DSM IV Diagnostic Criteria. Journal of Alzheimer's Disease, 2018, 66, 1471-1481.	1.2	72
18	Amyotrophic Lateral Sclerosis and soccer: an internet survey of 29 Italian players. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 364-369.	0.2	5

#	Article	IF	CITATIONS
19	Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. Oncology Letters, 2017, 13, 2903-2908.	0.8	8
20	Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels. Oncology Letters, 2016, 12, 2389-2394.	0.8	29
21	The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. Angiogenesis, 2014, 17, 831-838.	3.7	13
22	Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. Aids, 2012, 26, 909-919.	1.0	33
23	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	1.1	56
24	Pharmacological management of Kaposi's sarcoma. Expert Opinion on Pharmacotherapy, 2011, 12, 1669-1690.	0.9	10
25	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors ⟨i⟩via⟨ i⟩ a proteasomeâ€independent block of angiogenesis and matrix metalloproteinases. International Journal of Cancer, 2011, 128, 82-93.	2.3	40
26	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. Aids, 2009, 23, 534-538.	1.0	31
27	Macrophages Transmit Human Immunodeficiency Virus Type 1 Products to CD4-Negative Cells: Involvement of Matrix Metalloproteinase 9. Journal of Virology, 2007, 81, 9078-9087.	1.5	20
28	Control of Human Herpes Virus Type 8-Associated Diseases by NK Cells. Annals of the New York Academy of Sciences, 2007, 1096, 37-43.	1.8	8
29	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. Journal of General Virology, 2006, 87, 1625-1634.	1.3	26
30	HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway. Molecular Biology of the Cell, 2006, 17, 1985-1994.	0.9	66
31	The use of HAART for biological tumour therapy. Journal of HIV Therapy, 2006, 11, 53-6.	0.6	6
32	Treatment of Kaposi's sarcoma—an update. Anti-Cancer Drugs, 2002, 13, 977-987.	0.7	24
33	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Medicine, 2002, 8, 225-232.	15.2	299
34	Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor. Molecular Biology of the Cell, 2001, 12, 2934-2946.	0.9	110